Trial Profile
Phase III study of the efficacy and tolerability of lenvatinib monotherapy in patients with malignant melanoma
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 25 Nov 2009
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary)
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Sponsors Eisai Co Ltd
- 25 Nov 2009 New trial record.